ETF · Global X
GNOG Global X Genomics & Biotechnology UCITS ETF
ISIN IE00BM8R0N95London Stock Exchange: GNOGMirae Asset Global Investments Co., Ltd.
- Healthcare
- ETF
- ISA
- SIPP
- Accumulating
Latest close
LSE£8.30
on
- Ongoing charge
- 0.50% a year
- Fund size
- £107m
As of , at least 15 min delayed
At a glance
As of 13/11/2026, GNOG (Global X Genomics & Biotechnology UCITS ETF, ISIN IE00BM8R0N95) closed at £8.30 on the London Stock Exchange. Its ongoing charge is 0.50% a year (about £50 on £10,000). Over the five years to 13/11/2026 its price changed by −26.8%, or −42.9% after UK CPIH inflation.
Past returns
- 1 year to 13/11/2026
- +43.1%
- +38.0% after inflation (UK CPIH)
- 3 years to 13/11/2026
- +51.1%
- +36.5% after inflation (UK CPIH)
- 5 years to 13/11/2026
- −26.8%
- −42.9% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £732 on 13/11/2026 — about £571 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: as reported (delayed data) and worked out from recorded daily closes. Inflation: UK CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of Global X Genomics & Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund): 2022 −29.7%, 2023 −11.3%, 2024 −13.3%, 2025 +7.1%; 2026 to 13/11/2026 +37.1%. Returns of Global X Genomics & Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +77.6%; to 30/09/2025: −9.1%; to 30/09/2024: +0.2%; to 30/09/2023: −27.7%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +37.1% | +32.7% | |
| to | +7.1% | +3.4% | |
| to | −13.3% | −16.2% | |
| −11.3% | −14.9% | ||
| −29.7% | −35.7% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +77.6% | +71.3% |
| from | −9.1% | −12.7% |
| from | +0.2% | −2.3% |
| from | −27.7% | −32.0% |
As of , inflation: UK CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
29.4%over 5 years
| 1 year | 31.1% |
|---|---|
| 3 years | 29.2% |
| 5 years | 29.4% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since November 2021
- −64.9%
- From to
- Lowest 12-month return
- −35.4%
- 12 months to
- Highest 12-month return
- +91.3%
- 12 months to
- Below its highest weekly close since November 2021
- 25.9%
- High of , latest
In words: Volatility of Global X Genomics & Biotechnology UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 31.1% over 1 year, 29.2% over 3 years, 29.4% over 5 years. Largest fall in the price of Global X Genomics & Biotechnology UCITS ETF since November 2021, in pounds: −64.9% from 19/11/2021 to 11/04/2025. The lowest 12-month return of Global X Genomics & Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) since November 2021 was −35.4% (12 months to 11/04/2025); the highest was +91.3% (12 months to 25/09/2026). On 13/11/2026 the price of Global X Genomics & Biotechnology UCITS ETF was 25.9% below its highest weekly close since November 2021 (19/11/2021), in pounds.
As of , price, with income reinvested in the fund
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.50%
- a year
- On £10,000
- £50
- a year, roughly
- Over five years
- £248
- of £10,000, before growth
- 24 charge less
- 0 the same
- 4 charge more
Ongoing charge of Global X Genomics & Biotechnology UCITS ETF 0.50% a year. Compared on 14/11/2026, 4 of the 28 other healthcare funds charge more, 0 the same and 24 less (share classes counted once).
As of
A lower charge is not a promise of a higher return: what the fund holds matters more.
As of
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
Global X Genomics & Biotechnology UCITS ETF is an exchange-traded fund (ETF) from Global X, launched in 2021.
It tracks the Solactive Genomics v2 Index - Benchmark TR Net.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.5% a year — about £50 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- GNOG
- ISIN
- IE00BM8R0N95
- Also listed as
- GNOM (London Stock Exchange, US dollars), GN0M (Xetra, euros)
- Provider
- Global X
- Tracks
- Solactive Genomics v2 Index
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Accumulating
- Income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
- Ongoing charge
- 0.50% a year · about £50 on £10,000
- Fund size
- £107m
- Launched
- Domicile
- Ireland
- UK reporting fund status
- Yes — on HMRC’s list of reporting funds (list of )
- Reporting fund since . What reporting fund status means
- Can usually be held in
- ISA and SIPP
- Check with your platform: each decides which funds it offers.
- Currency hedged
- No
- Price currency
- Pounds (GBP)
- Category
- Healthcare
Price chart
Over the last year, the closing price went from £5.78 on 14/11/2025 to £8.30 on 13/11/2026 (+43.6%). The lowest close shown was £5.62 on 27/03/2026 and the highest £9.42 on 25/09/2026.
One close a week. Before 18/09/2026 the closes are from the weekly price history for this listing; from then on, the closing prices we have recorded.
As of , at least 15 min delayed
Five years of prices, and after inflation
262 weekly closes, from 12/11/2021 to 13/11/2026. The same history in November 2026 pounds, adjusted with CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1, 3 and 5 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 211 rolling 12-month returns since November 2021, and of 107 rolling three-year returns, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The largest fall since November 2021, in pounds, with how many weeks it took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Moves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core MSCI World UCITS ETF, over the three years to 13/11/2026 (154 weeks).
Pro
Pro — currently by invitation
Pro includes moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of GNOG?
The ongoing charge of GNOG is 0.50% a year — about £50 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Global X Genomics & Biotechnology UCITS ETF 0.50% a year. Compared on 14/11/2026, 4 of the 28 other healthcare funds charge more, 0 the same and 24 less (share classes counted once).
What does GNOG track?
GNOG tracks the Solactive Genomics v2 Index - Benchmark TR Net.
Is GNOG accumulating or distributing?
GNOG is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
What is the ISIN of GNOG?
The ISIN of GNOG is IE00BM8R0N95. An ISIN identifies one exact share class of a fund; GNOG is its ticker on the London Stock Exchange. The same share class is also listed as GNOM (London Stock Exchange, US dollars) and GN0M (Xetra, euros).
What were GNOG’s returns in each of the last five years?
Calendar-year returns of GNOG in pounds (price, with income reinvested in the fund): 2022 −29.7%, 2023 −11.3%, 2024 −13.3%, 2025 +7.1%; 2026 to 13/11/2026 +37.1%. Past performance is not a guide to future returns.
How has GNOG done after inflation?
Over the five years to 13/11/2026 GNOG’s price changed by −26.8%, or −42.9% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £3.4bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £2.7bn
- DRDRiShares Healthcare Innovation UCITS ETF0.40% a year · £1.3bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £1.2bn
- BTEKiShares NASDAQ US Biotechnology UCITS ETF0.35% a year · £1.0bn
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £833m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £798m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £792m
Fund documents and methods
Methodology:ReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.